Patents by Inventor Johan Frostegärd

Johan Frostegärd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11801283
    Abstract: The invention relates to novel methods, uses and compositions for the prophylaxis or the treatment of osteoarthritis, and conditions associated therewith.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: October 31, 2023
    Assignee: ANNEXIN PHARMACEUTICALS AB
    Inventors: Johan Frostegård, Anna Frostegård, Divya Thiagarajan
  • Publication number: 20210389310
    Abstract: Low levels of antibodies reactive with oxidised Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardivacular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunisation and therapy of these diseases and conditions are provided.
    Type: Application
    Filed: March 29, 2021
    Publication date: December 16, 2021
    Applicant: ANNEXIN PHARMACEUTICALS AB
    Inventor: Johan FROSTEGÅRD
  • Publication number: 20210032359
    Abstract: Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells.
    Type: Application
    Filed: August 11, 2020
    Publication date: February 4, 2021
    Inventor: Johan FROSTEGÅRD
  • Patent number: 10752680
    Abstract: Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: August 25, 2020
    Assignee: ATHERA BIOTECHNOLOGIES AB
    Inventor: Johan Frostegård
  • Publication number: 20200262906
    Abstract: Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells.
    Type: Application
    Filed: May 6, 2020
    Publication date: August 20, 2020
    Inventor: Johan FROSTEGÅRD
  • Patent number: 10669332
    Abstract: Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: June 2, 2020
    Assignee: ATHERA BIOTECHNOLOGIES AB
    Inventor: Johan Frostegård
  • Publication number: 20190374604
    Abstract: The invention relates to novel methods, uses and compositions for the prophylaxis or the treatment of osteoarthritis, and conditions associated therewith.
    Type: Application
    Filed: February 8, 2018
    Publication date: December 12, 2019
    Inventors: Johan FROSTEGÅRD, Anna FROSTEGÅRD, Divya THIAGARAJAN
  • Publication number: 20190086395
    Abstract: Low levels of antibodies reactive with oxidised Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardivacular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunisation and therapy of these diseases and conditions are provided.
    Type: Application
    Filed: July 26, 2018
    Publication date: March 21, 2019
    Inventor: Johan FROSTEGÅRD
  • Patent number: 10222382
    Abstract: In subjects with hypertension, increases in intima-media thickness (IMT) at four years were less in subjects also having high autoantibodies particularly IgM, to phosphorylcholine. The presence or absence of autoantibodies, particularly IgM, against phosphrylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determining antibodies, particularly IgM antibodies, toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of antibodies, particularly IgM antibodies, can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH)-phosphorylcholine conjugate.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: March 5, 2019
    Assignee: ATHERA BIOTECHNOLOGIES AB
    Inventors: Ulf De Faire, Johan Frostegård
  • Patent number: 10060908
    Abstract: Low levels of antibodies reactive with oxidized Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunization and therapy of these diseases and conditions are provided.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: August 28, 2018
    Assignee: MEDIRISTA BIOTECHNOLOGIES AB
    Inventor: Johan Frostegård
  • Publication number: 20180186870
    Abstract: Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells.
    Type: Application
    Filed: May 9, 2016
    Publication date: July 5, 2018
    Inventor: Johan FROSTEGÅRD
  • Publication number: 20180148502
    Abstract: Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells.
    Type: Application
    Filed: May 9, 2016
    Publication date: May 31, 2018
    Inventor: Johan FROSTEGÅRD
  • Publication number: 20180140668
    Abstract: A method for the prophylaxis or treatment of restenosis comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. A method for the treatment of stenosis in a patient comprising performing an intervention for the treatment of stenosis in conjunction with administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof. A pharmaceutical composition comprising a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof for the prophylaxis or treatment of restenosis. A drug eluting stent, wherein the drug is Annexin A5 or a functional analogue or variant thereof, and a method of making such a stent.
    Type: Application
    Filed: January 11, 2018
    Publication date: May 24, 2018
    Inventors: Knut PETTERSSON, Johan FROSTEGÅRD, Ola CAMBER
  • Patent number: 9901614
    Abstract: A method for the prophylaxis or treatment of restenosis comprising administering a therapeutically effective amount of Annexin A5 or a functional analog or variant thereof to a patient in need of such treatment. A method for the treatment of stenosis in a patient comprising performing an intervention for the treatment of stenosis in conjunction with administering a therapeutically effective amount of Annexin A5 or a functional analog or variant thereof. A pharmaceutical composition comprising a therapeutically effective amount of Annexin A5 or a functional analog or variant thereof for the prophylaxis or treatment of restenosis. A drug eluting stent, wherein the drug is Annexin A5 or a functional analog or variant thereof, and a method of making such a stent.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: February 27, 2018
    Assignee: Annexin Pharmaceuticals AB
    Inventors: Knut Pettersson, Johan Frostegård, Ola Camber
  • Publication number: 20170239329
    Abstract: The present invention provides Annexin A5 for use in a prophylactic or therapeutic method of preventing, reducing, delaying the onset of, or delaying the progression of, direct viral damage to the vascular system and/or immune system, in a subject, wherein the viral infection is caused by a virus selected from the group consisting of (a) a virus capable of causing hemorrhagic fever (VHF), and (b) a virus that presents phosphatidylserine (PS) and mediates cell infection and/or internalisation through PS binding.
    Type: Application
    Filed: October 15, 2015
    Publication date: August 24, 2017
    Inventors: Johan FROSTEGÅRD, Anna FROSTEGÅRD, Marianne SVÄRD, Thomas ANDERSSON
  • Patent number: 9682122
    Abstract: The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analog or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and/or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: June 20, 2017
    Assignee: ANNEXIN PHARMACEUTICALS AB
    Inventors: Johan Frostegård, Knut Pettersson
  • Patent number: 9649355
    Abstract: The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analog or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and/or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: May 16, 2017
    Assignee: ANNEXIN PHARMACEUTICALS AB
    Inventors: Johan Frostegård, Knut Pettersson
  • Publication number: 20160250284
    Abstract: A method for the prophylaxis or treatment of restenosis comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. A method for the treatment of stenosis in a patient comprising performing an intervention for the treatment of stenosis in conjunction with administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof. A pharmaceutical composition comprising a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof for the prophylaxis or treatment of restenosis. A drug eluting stent, wherein the drug is Annexin A5 or a functional analogue or variant thereof, and a method of making such a stent.
    Type: Application
    Filed: March 1, 2016
    Publication date: September 1, 2016
    Inventors: Knut PETTERSSON, Johan Frostegård, Ola CAMBER
  • Publication number: 20160251426
    Abstract: Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells.
    Type: Application
    Filed: May 9, 2016
    Publication date: September 1, 2016
    Inventor: Johan FROSTEGÅRD
  • Publication number: 20160251427
    Abstract: Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells.
    Type: Application
    Filed: May 9, 2016
    Publication date: September 1, 2016
    Inventor: Johan FROSTEGÅRD